PharmTech Weekly Roundup—August 28, 2026

This week on PharmTech.com, industry experts discussed a variety of topics that touched on the theme of control, including controlling manufacturing decisions, hold times, and nitrosamine risks. This week also saw a wave of pipeline and dealmaking news, from a 60% survival benefit in pancreatic cancer to a $2.25 billion consolidation play, that's reshaping how much formulation and manufacturing capacity the industry will need next.

In the News

In news this week, the FDA's approval of Revolution Medicines' treatment for metastatic pancreatic cancer cut the risk of death by 60% against chemotherapy, validating RAS(ON) inhibition as a genotype-agnostic, all-oral approach set to influence oncology manufacturing.

GSK’s priority-review filing for Jemperli in previously untreated rectal cancer could let patients skip chemotherapy, radiation, and surgery entirely, a shift that would also strain fill-finish capacity and cold-chain planning for an already-established biologic.

McKesson's $2.25 billion acquisition of Precision Medicine Group, which CEO Brian Tyler called a “meaningful step” in the company's oncology strategy, signals that trial sponsors should expect more vertically integrated, single-vendor paths from data to commercial launch.

REGENXBIO's clinical hold on its Hunter syndrome gene therapy RGX-121, triggered by asymptomatic spine MRI findings investigators call likely benign, shows how postmarket-style imaging surveillance is now entering into pre-approval gene therapy programs.

In the United Kingdom, a new Centrix Pharma Solutions–University of Sussex partnership aims to turn siloed formulation and process data into predictive, decision-ready analytics, with Sussex's Kate Thorpe framing the goal as building data science capability that outlasts the project itself.

Expert Discussion and Commentary

Experts explained a variety of topics this week on PharmTech.com.

Robert Dream, in PharmTech's ongoing Pharma Fundamentals series, makes the case that hold-time limits in biopharmaceutical manufacturing aren't spelled out by regulators. Manufacturers should set, justify, and defend their own standards.

Formulation scientist Gary Watts states that, as antibody-drug conjugates, bispecifics, and fusion proteins crowd the pipeline, stability must be engineered in from day one, with machine-learning-driven preformulation screening increasingly deciding whether a molecule ever reaches a syringe.

Brian Drapeau warns that pharma’s real AI risk isn’t whether agentic systems produce correct answers, but whether organizations have actually mapped which decisions those agents are authorized to make before a quality unit ever sees the output.

Hovione’s Anthony Tantuccio makes the case that continuous direct compression can bypass granulation for select spray-dried dispersion formulations, shifting tablet development from a default assumption to a deliberate, material-property-driven choice.

European Frontrunners’ columnist, Cheryl Barton, surveys a fast-maturing European bioprinting landscape, where firms are pushing 3D bioprinting toward implantable tissue and organ-on-a-chip drug screening faster than regulation can keep pace, even with the European Medicines Agency’s new additive manufacturing guidance.

Chris Williams of Alcami traces how nitrosamine risk management has shifted from screening for a short list of known impurities to mapping the mechanistic pathways that let nitrites and amines form them in the first place across a product's entire lifecycle.

Across AI oversight, hold-time and nitrosamine frameworks, and a run of novel oncology and gene-therapy news, this week's throughline is that pharma's ability to move fast on new modalities is increasingly gated by how rigorously it can define, document, and defend the decisions behind them. For the full stories, visit PharmTech.com.